A cost-performance analysis of Canada’s supervised injection site A cost-efficiency analysis of Insite, Canada’s only supervised safe injection site in Vancouver, concludes that it outcomes in $14 million in savings and health gains of 920 life-years over 10 years. The study . Thus, Insite is almost certainly cost-saving to Canadian society.SAS software, edition 9.1 , and the R program writing language were used for statistical analyses. Results Trial Participants Between 2004 and August 2009 April, a complete of 1454 sufferers with unprotected left main coronary artery stenosis were enrolled . We randomly assigned 600 of these sufferers to PCI with sirolimus-eluting stents or even to CABG . The remaining 854 patients did not go through randomization for the reasons indicated in Table 1 in the Supplementary Appendix but had been included in the registry.